Literature DB >> 22262060

The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma.

Jane A Cipollone1, Marcia L Graves, Martin Köbel, Steve E Kalloger, Tak Poon, C Blake Gilks, Kelly M McNagny, Calvin D Roskelley.   

Abstract

High grade serous ovarian tumors often metastasize transperitoneally, a process that begins when small tumor nodules de-adhere and are released into the fluid of the abdominal cavity where they float freely to reach new sites on the peritoneal wall. Podocalyxin, a small anti-adhesive sialomucin, has been shown to contribute to non-adhesive membrane domain formation in some epithelia and is overexpressed in a variety of cancers. We therefore assessed podocalyxin expression on a previously characterized tissue microarray and found that 87% (169/194) of high grade serous epithelial ovarian carcinomas were positive for podocalyxin. In addition, cell surface localization of podocalyxin was associated with a significant decrease in disease-free survival in these tumors. When podocalyxin was force-expressed in serous ovarian carcinoma-derived OVCAR-3 cells it was targeted to the cell surface and it decreased the adhesion of these cells to mesothelial monolayers, fibronectin and immobilized β1 integrin-binding antibodies. This decrease in adhesion was associated with a modest decrease in cell surface β1 integrin. In monolayer culture, podocalyxin was targeted to the free, apical domains of OVCAR-3 cells and it appeared to decrease β1 integrin levels on the attached basolateral domains of the same cells. Furthermore, in 3-dimensional basement membrane gel culture, the cells formed small, cohesive nodules and podocalyxin localized to membrane domains at the cell-basement membrane interface. Therefore, podocalyxin's ability to facilitate the formation of non-adhesive membrane domains may contribute to the formation of free-floating high grade serous tumor nodules during the initial steps of transperitoneal metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22262060     DOI: 10.1007/s10585-011-9446-0

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  50 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  The glomerular epithelial cell anti-adhesin podocalyxin associates with the actin cytoskeleton through interactions with ezrin.

Authors:  Robert A Orlando; Tetsuro Takeda; Beverly Zak; Sandra Schmieder; Vivian M Benoit; Tammie McQuistan; Heinz Furthmayr; Marilyn G Farquhar
Journal:  J Am Soc Nephrol       Date:  2001-08       Impact factor: 10.121

3.  Symptomatology of ovarian cancer.

Authors:  F Flam; N Einhorn; K Sjövall
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1988-01       Impact factor: 2.435

4.  Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts.

Authors:  Jasmin Teresa Ney; Hui Zhou; Bence Sipos; Reinhard Büttner; Xin Chen; Günter Klöppel; Ines Gütgemann
Journal:  Hum Pathol       Date:  2006-11-29       Impact factor: 3.466

5.  Podocalyxin in rat platelets and megakaryocytes.

Authors:  A Miettinen; M L Solin; J Reivinen; E Juvonen; R Väisänen; H Holthöfer
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

6.  Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer.

Authors:  S A Cannistra; C Ottensmeier; J Niloff; B Orta; J DiCarlo
Journal:  Gynecol Oncol       Date:  1995-08       Impact factor: 5.482

7.  Serous carcinogenesis in the fallopian tube: a descriptive classification.

Authors:  Elke Jarboe; Ann Folkins; Marisa R Nucci; David Kindelberger; Ronny Drapkin; Alexander Miron; Yonghee Lee; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2008-01       Impact factor: 2.762

Review 8.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

9.  MEK1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition.

Authors:  Jan Pinkas; Philip Leder
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

10.  Cell motility and spreading are suppressed by HOXA4 in ovarian cancer cells: possible involvement of beta1 integrin.

Authors:  Christian Klausen; Peter C K Leung; Nelly Auersperg
Journal:  Mol Cancer Res       Date:  2009-09-01       Impact factor: 5.852

View more
  25 in total

1.  Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.

Authors:  K Boman; A H Larsson; U Segersten; E Kuteeva; H Johannesson; B Nodin; J Eberhard; M Uhlén; P-U Malmström; K Jirström
Journal:  Br J Cancer       Date:  2013-05-07       Impact factor: 7.640

2.  Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer.

Authors:  Anna Larsson; Marie Fridberg; Alexander Gaber; Björn Nodin; Per Levéen; Göran Jönsson; Mathias Uhlén; Helgi Birgisson; Karin Jirström
Journal:  BMC Cancer       Date:  2012-07-08       Impact factor: 4.430

3.  A Direct Podocalyxin-Dynamin-2 Interaction Regulates Cytoskeletal Dynamics to Promote Migration and Metastasis in Pancreatic Cancer Cells.

Authors:  Bin Sheng Wong; Daniel J Shea; Panagiotis Mistriotis; Soontorn Tuntithavornwat; Robert A Law; Jake M Bieber; Lei Zheng; Konstantinos Konstantopoulos
Journal:  Cancer Res       Date:  2019-04-11       Impact factor: 13.312

4.  Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma.

Authors:  Margareta Heby; Jakob Elebro; Björn Nodin; Karin Jirström; Jakob Eberhard
Journal:  BMC Clin Pathol       Date:  2015-05-30

5.  Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.

Authors:  Kapo Saukkonen; Jaana Hagström; Harri Mustonen; Anne Juuti; Stig Nordling; Christian Fermér; Olle Nilsson; Hanna Seppänen; Caj Haglund
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

6.  Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy.

Authors:  Kimberly A Snyder; Michael R Hughes; Bradley Hedberg; Jill Brandon; Diana Canals Hernaez; Peter Bergqvist; Frederic Cruz; Kelvin Po; Marcia L Graves; Michelle E Turvey; Julie S Nielsen; John A Wilkins; Shaun R McColl; John S Babcook; Calvin D Roskelley; Kelly M McNagny
Journal:  Breast Cancer Res       Date:  2015-03-27       Impact factor: 6.466

7.  Podocalyxin as a Prognostic Marker in Gastric Cancer.

Authors:  Alli Laitinen; Camilla Böckelman; Jaana Hagström; Arto Kokkola; Christian Fermér; Olle Nilsson; Caj Haglund
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

8.  Podocalyxin-like protein expression in primary colorectal cancer and synchronous lymph node metastases.

Authors:  Anna H Larsson; Björn Nodin; Ingvar Syk; Ingrid Palmquist; Mathias Uhlén; Jakob Eberhard; Karin Jirström
Journal:  Diagn Pathol       Date:  2013-07-02       Impact factor: 2.644

9.  Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.

Authors:  Zev A Binder; I-Mei Siu; Charles G Eberhart; Colette Ap Rhys; Ren-Yuan Bai; Verena Staedtke; Hao Zhang; Nicolas R Smoll; Steven Piantadosi; Sara G Piccirillo; Francesco Dimeco; Jon D Weingart; Angelo Vescovi; Alessandro Olivi; Gregory J Riggins; Gary L Gallia
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

10.  Increased cycling cell numbers and stem cell associated proteins as potential biomarkers for high grade human papillomavirus+ve pre-neoplastic cervical disease.

Authors:  Maurice Canham; Chara Charsou; June Stewart; Sharon Moncur; Laura Hoodless; Ramya Bhatia; Duanduan Cong; Heather Cubie; Camille Busby-Earle; Alistair Williams; Victoria McLoughlin; John D M Campbell; Kate Cuschieri; Sarah Howie
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.